FORT WORTH, Texas, July 30 Wound Care Innovations, LLC, asubsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM),announced today an evidence based study with a NE podiatric clinic evaluatingthe clinical performance of their advanced wound care collagen product,CellerateRx(R), on diabetic venous ulcers. "According to data released by theCenters for Disease Control and Prevention, diabetes now affects nearly 24million people in the United States alone," states Cathy Bradshaw, Presidentof Wound Care Innovations. Venous stasis ulcers of the lower extremity is acommon problem among diabetic patients and presents significant quality oflife issues for them as well as tremendous costs to the healthcare system. Ithas been estimated that venous ulcers cause the loss of approximately 2million working days and incur treatment costs of approximately $3 billion peryear in the United States.(1) "We have had very positive feedback fromclinicians using CellerateRx(R) on these types of wounds. We look forward toproviding this data to the medical community," Bradshaw said.
(1) New England Journal of Medicine, Bergan et al
About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. (WNDM), Worth, Texas, markets anddistributes wound care products to the healthcare market under patentedtechnology licensed to the Company. The Company is positioned and seeks to bea leading provider of wound care products. For more information visitwww.Celleraterx.com .
"Safe Harbor" Statement: Under The Private Securities Litigation ReformAct of 1995: The statements in the press release that relate to the company'sexpectations with regard to the future impact on the company's results fromnew products in development are "forward-looking statements," within themeaning of the Private Securities Litigation Reform Act of 1995. Since thisinformation may contain statements that involve risk and uncertainties and aresubject to change at any time, the company's actual results may differmaterially from expected results. This document may contain forward-lookingstatements concerning the Company's operations, current and future performanceand financial condition. These items involve risks and uncertainties such asproduct demand, market and customer acceptance, the effect of economicconditions, competition, pricing, the ability to consummate and integrateacquisitions, and other risks and uncertainties detailed in the Company's SECfilings. The Company undertakes no obligation to revise any of thesestatements to reflect the future circumstances or the occurrence ofunanticipated events.
SOURCE Wound Management Technologies, Inc.